| |
New HCV Polymerase Drug
|
| |
| |
Inhibitex Announces Data Presentation at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
Mon Oct 26, 2009 11:29am EDT
INX-189 Exhibits Favorable Pharmacology Profile in Preclinical Studies
ATLANTA-- Inhibitex, Inc. (NASDAQ: INHX) announced today that a poster presentation describing preclinical data on INX-189, the lead compound from its HCV nucleotide polymerase inhibitor program, will be presented by Dr. Joseph M. Patti, Chief Scientific Officer and Senior Vice President of R&D, at the 60th Annual Meeting of the American Association for the Study of Liver Diseases
(AASLD) in Boston, MA. The full abstract can be viewed at the AASLD website at
www.aasld.org.
The poster (#1611 Patti, et al), entitled "Pharmacological Properties and In Vitro Characterization of INX-189, a Liver Targeted Phosphoramidate Nucleoside Analogue Inhibitor of NS5b" will be presented in the HCV Therapy: Preclinical and Early Clinical Development session from 8:00 am - 1:00 pm on Tuesday, November 3rd, 2009.
About HCV and Protides
Hepatitis C is a disease of the liver caused by the hepatitis C virus (HCV). It is estimated that approximately 4 million Americans and 170 million individuals worldwide are infected with HCV. HCV can cause chronic liver disease, cirrhosis and cancer, and is the leading cause of liver transplant in the United States. Inhibitex is developing a series of proprietary phosphoramidates, or protide
nucleoside inhibitors, that target the RNA-dependent RNA polymerase (NS5b) of HCV. Protides are designed to by-pass the rate limiting first step in the formation of the active nucleoside triphosphate. INX-189 is a protide of a 2'-C-methyl guanosine analogue. The Company believes that its protides possess several pharmacological advantages over nucleosides alone and potentially other nucleotide prodrugs. These advantages include greater potency, a rapid
conversion of the protide into its active form in the liver, and potentially less toxicity due to reduced systemic exposure of the nucleoside.
About Inhibitex
Inhibitex, Inc., headquartered in Alpharetta, Georgia, is a biopharmaceutical company focused on developing products to treat serious infectious diseases. In addition to INX-189, the Company's pipeline includes FV-100, its clinical-stage
nucleoside analogue in Phase II development for the treatment of herpes zoster (shingles). The Company has also licensed the use of its proprietary MSCRAMM® protein technology to Wyeth for the development of staphylococcal vaccines.
For additional information about the Company, please visit www.inhibitex.com.
Inhibitex, Inc.
Russell H. Plumb, 678-746-1136
Chief Executive Officer
www.inhibitex.com
|
|
| |
| |
|
|
|
